Company news
Abeona Therapeutics Inc. news
Latest news releases, newest first. Pick a year for every news release, call and deck from that year.
Abeona Therapeutics Announces Pricing of $25 Million Private Placement of Convertible Redeemable Preferred Stock
April 28, 2022
Abeona Therapeutics Announces Presentation at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
April 28, 2022
Abeona Therapeutics Announces Strategy Update and 2021 Financial Results
March 30, 2022
Abeona Therapeutics to Participate in the Cantor Fitzgerald Virtual Rare Orphan Disease Summit
March 27, 2022
Abeona Therapeutics Achieves Target Enrollment in Pivotal Phase 3 VIITAL™ Study of EB-101 in RDEB
March 13, 2022
Abeona Therapeutics Issues Letter to Shareholders
December 21, 2021
Abeona Therapeutics Announces Pricing of Public Offering of Common Stock and Warrants
December 16, 2021
Abeona Therapeutics Announces Public Offering of Common Stock and Warrants
December 15, 2021
Abeona Therapeutics Announces Support of EB Research Partnership's Venture Into Cures Event to Raise Awareness for Education and Research of Epidermolysis Bullosa
November 17, 2021
Abeona Therapeutics Announces Presentation on Pivotal Transpher A Study of ABO-102 in MPS IIIA at the 14th ICIEM Conference
November 16, 2021
Abeona Therapeutics Announces Participation at the Jefferies London Healthcare Conference
November 15, 2021
Abeona Therapeutics Reports Third Quarter Financial Results
November 14, 2021
Abeona Therapeutics to Present at Jefferies Gene Therapy/Editing Summit
October 20, 2021
Abeona Therapeutics Announces Clinical Data Presentations at Upcoming Scientific Congresses
October 12, 2021
Abeona Therapeutics Appoints Gene Therapy Quality Leader Jon Voss as Vice President, Head of Quality
October 11, 2021
Abeona Announces New Chairman, Executive Leadership Promotions and Key Talent Additions for Final Push Towards Two Biologics License Application (BLA) Filings
September 20, 2021
Abeona Therapeutics to Present at Upcoming Investor Conferences
September 6, 2021
Abeona Therapeutics Appoints Edward Carr as Chief Financial Officer
August 9, 2021
Abeona Therapeutics Reports Second Quarter Financial Results
July 27, 2021
Abeona Therapeutics Announces Successful Type B Meeting with U.S. FDA for ABO-102 AAV-based Gene Therapy in Sanfilippo Syndrome Type A (MPS IIIA)
July 27, 2021
Abeona Therapeutics Announces New MRI Data Showing Increased Brain Volume in Young Patients with Sanfilippo Syndrome Type A (MPS IIIA) After Treatment with ABO-102 Gene Therapy
July 25, 2021
Abeona Therapeutics Activates Second Clinical Trial Site in EB-101 Pivotal Phase 3 VIITAL™ Study for Recessive Dystrophic Epidermolysis Bullosa
July 22, 2021
Abeona Therapeutics Announces Updated EB-101 Phase 1/2a Clinical Results in Recessive Dystrophic Epidermolysis Bullosa at the Society for Pediatric Dermatology 46th Annual Meeting
July 6, 2021
Abeona Therapeutics to Present at Jefferies Virtual Healthcare Conference
June 1, 2021
Abeona Therapeutics Issues Letter to Stockholders
May 25, 2021
Abeona Therapeutics Appoints Head of Research & Clinical Development
May 24, 2021
Abeona Therapeutics Reports First Quarter Financial Results
May 17, 2021
Abeona Therapeutics Announces Presentation on New Preclinical Data Supporting the Potential of Cre-Mediated Dual AAV Vector Technology to Enable Delivery of Large Genes Targeted for Treatment of Stargardt Disease at ARVO 2021 Annual Meeting
April 19, 2021
Abeona Therapeutics Appoints Two Industry Leaders as New Independent Members to Its Board of Directors
April 18, 2021
Abeona Therapeutics Announces Appointment of Two New Independent Members to its Board of Directors
March 24, 2021
Abeona Therapeutics Announces 2020 Financial Results and Recent Operational Progress
March 23, 2021
Abeona Therapeutics Announces Appointment of Michael Amoroso as Chief Executive Officer
March 21, 2021
Abeona Therapeutics to Present at the 10th Annual SVB Leerink Global Healthcare Conference
February 21, 2021
New Positive Phase 1/2 Interim Data Presented at WORLDSymposium™ Shows Neurocognitive Development of Young MPS IIIA Patients Preserved up to Three Years Following Treatment with Abeona’s ABO-102 Gene Therapy
February 11, 2021
Abeona Therapeutics Announces Clinical Investigator Webinar to Review ABO-102 and ABO-101 Clinical Data Presented at the 17th Annual WORLDSymposium™
February 1, 2021
Abeona Therapeutics Announces Successful Type B Meeting with FDA for Pivotal Phase 3 VIITAL™ Study of EB-101 in Recessive Dystrophic Epidermolysis Bullosa (RDEB)
January 24, 2021
Abeona Therapeutics Announces Acceptance of Late-Breaker Abstracts Highlighting New Clinical Data for Novel AAV-based Gene Therapies in MPS IIIA and MPS IIIB at WORLDSymposium™
December 20, 2020
Abeona Therapeutics Announces the Appointment of Michael Amoroso as Chief Operating Officer
October 26, 2020
Abeona Therapeutics’ Board of Directors Forms Special Committee to Oversee Operations, Develop Strategic Direction and Leadership Plan
October 5, 2020
Abeona Therapeutics Announces Leadership and Board Transitions
September 27, 2020
Abeona Therapeutics to Participate in Upcoming Investor Conferences
September 7, 2020
Abeona Therapeutics and Taysha Gene Therapies Enter into Licensing and Inventory Purchase Agreements for ABO-202, a Clinical Stage, Novel, One-time Gene Therapy for CLN1 Disease
August 16, 2020
Abeona Therapeutics Reports Second Quarter Financial Results and Business Updates
August 9, 2020
Abeona Therapeutics Announces Two Presentations Related to Its RDEB Clinical Program at the Society for Pediatric Dermatology 45th Annual Meeting
July 9, 2020
Abeona Therapeutics Announces Appointment of Michael Amoroso as Chief Commercial Officer
July 8, 2020
Abeona Therapeutics Reinitiates Enrollment in EB-101 Pivotal Phase 3 VIITAL™ Study in RDEB after COVID-19 Related Pause and Announces Progress in Patient Enrollment in MPS III Studies
July 7, 2020
Abeona Therapeutics Announces Upcoming Data Presentations at the Society for Pediatric Dermatology 45th Annual Meeting
June 17, 2020
Abeona Therapeutics Further Strengthens Board with Appointment of Two New Independent Directors
June 16, 2020
Abeona Therapeutics to Present at the Jefferies 2020 Virtual Healthcare Conference
May 27, 2020
Abeona Therapeutics Reports First Quarter Financial Results and Business Updates
May 5, 2020
Calls
The 5 newest of 19 calls. Every call is listed under its year.
- Abeona Therapeutics (NASDAQ:ABEO) Q2 2026 Earnings Call
Aug 13, 2026
Transcript - Abeona Therapeutics (NASDAQ:ABEO) Q1 2026 Earnings Call
May 13, 2026
Transcript - Abeona Therapeutics (NASDAQ:ABEO) Q4 2025 Earnings Call
Mar 17, 2026
Transcript - Abeona Therapeutics (NASDAQ:ABEO) Q3 2025 Earnings Call
Nov 12, 2025
Transcript - Abeona Therapeutics (NASDAQ:ABEO) Q1 2025 Earnings Call
May 15, 2025
Transcript
Decks
The 5 newest of 18 decks. Every deck is listed under its year.
- Investor Presentation (October 2026)
Investor deck · 19 slides · October 2026
- H.C. Wainwright 28th Annual Global Investment Conference (September 2026)
Conference · 19 slides · Sep 15, 2026
- Q2 2026 Earnings Presentation
Earnings · 22 slides · Aug 13, 2026
- Investor Presentation (June 2026)
Investor deck · 22 slides · Jun 10, 2026
- Q1 2026 Earnings Presentation
Earnings · 19 slides · May 13, 2026